171 related articles for article (PubMed ID: 14605880)
1. Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids.
Genç M; Castro Kreder N; Barten-van Rijbroek A; Stalpers LJ; Haveman J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):45-51. PubMed ID: 14605880
[TBL] [Abstract][Full Text] [Related]
2. Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue.
Fehlauer F; Muench M; Smid EJ; Slotman B; Richter E; Van der Valk P; Sminia P
Oncol Rep; 2006 Jan; 15(1):97-105. PubMed ID: 16328040
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor radioresponse in vivo by gemcitabine.
Milas L; Fujii T; Hunter N; Elshaikh M; Mason K; Plunkett W; Ang KK; Hittelman W
Cancer Res; 1999 Jan; 59(1):107-14. PubMed ID: 9892194
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity.
Pacini S; Milano F; Pinzani P; Pazzagli M; Gulisano M; Ruggiero M; Casamassima F
Tumori; 1999; 85(6):503-7. PubMed ID: 10774574
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair proficiency is not required for radioenhancement by gemcitabine.
van Bree C; Rodermond HM; de Vos J; Haveman J; Franken NA
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1504-9. PubMed ID: 15925456
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation.
Supiot S; Thillays F; Rio E; Gouard S; Morgenstern A; Bruchertseifer F; Mahé MA; Chatal JF; Davodeau F; Chérel M
Radiother Oncol; 2007 Apr; 83(1):97-101. PubMed ID: 17383762
[TBL] [Abstract][Full Text] [Related]
7. Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
Lambert B; De Ridder L; Slegers G; De Gelder V; Dierckx RA; Thierens H
Can J Physiol Pharmacol; 2004 Feb; 82(2):146-52. PubMed ID: 15052296
[TBL] [Abstract][Full Text] [Related]
8. [The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine].
Mose S; Karapetian M; Jüling-Pohlit L; Taborski B; Ramm U; Damrau M; Rahn A; Böttcher HD
Strahlenther Onkol; 1999 Feb; 175(2):78-83. PubMed ID: 10065143
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice.
Erlichman C; Vidgen D
Cancer Res; 1984 Nov; 44(11):5369-75. PubMed ID: 6488191
[TBL] [Abstract][Full Text] [Related]
10. Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.
Salem SD; Abou-Tarboush FM; Saeed NM; Al-Qadasi WD; Farah MA; Al-Buhairi M; Al-Harbi N; Alhazza I; Alsbeih G
Gene; 2012 May; 498(2):300-7. PubMed ID: 22353361
[TBL] [Abstract][Full Text] [Related]
11. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines.
Mose S; Karapetian M; Jüling-Pohlit L; Taborski B; Damrau M; Ramm U; Rahn A; Böttcher HD
Anticancer Res; 2000; 20(1A):401-5. PubMed ID: 10769687
[TBL] [Abstract][Full Text] [Related]
12. Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line.
Khaitan D; Chandna S; Arya MB; Dwarakanath BS
Cancer Biol Ther; 2006 Sep; 5(9):1142-51. PubMed ID: 16855378
[TBL] [Abstract][Full Text] [Related]
13. Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation.
Castro Kreder N; Van Bree C; Franken NA; Haveman J
J Radiat Res; 2004 Mar; 45(1):111-8. PubMed ID: 15133298
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine activity in cervical cancer cell lines.
Hernández P; Olivera P; Dueñas-Gonzalez A; Pérez-Pastenes MA; Zárate A; Maldonado V; Meléndez-Zajgla J
Cancer Chemother Pharmacol; 2001 Dec; 48(6):488-92. PubMed ID: 11800030
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines.
Sangar VK; Cowan R; Margison GP; Hendry JH; Clarke NW
Br J Cancer; 2004 Jan; 90(2):542-8. PubMed ID: 14735206
[TBL] [Abstract][Full Text] [Related]
16. Radiation enhancement by gemcitabine-mediated cell cycle modulations.
Mose S; Class R; Weber HW; Rahn A; Brady LW; Böttcher HD
Am J Clin Oncol; 2003 Feb; 26(1):60-9. PubMed ID: 12576927
[TBL] [Abstract][Full Text] [Related]
17. Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas.
Rosier JF; Bruniaux M; Husson B; Octave-Prignot M; Beauduin M; Grégoire V
Radiother Oncol; 2004 Jan; 70(1):55-61. PubMed ID: 15036853
[TBL] [Abstract][Full Text] [Related]
18. Maximizing therapeutic gain with gemcitabine and fractionated radiation.
Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547
[TBL] [Abstract][Full Text] [Related]
19. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
20. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine.
Weiss C; Grabenbauer GG; Sauer R; Distel L
Strahlenther Onkol; 2003 Feb; 179(2):93-8. PubMed ID: 12590319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
